Skip To The Main Content

NYSDA Publications

FDA Issues Final Guidance on Interchangeable Biologics

The United States Food and Drug Administration (FDA) has issued final guidance on bringing interchangeable biosimilar products to consumers in a more efficient way.  FDA notes that creating a pathway for interchangeable biologics, which may be substituted without the involvement of the prescriber, similar to how generic drugs are routinely substituted for brand name drugs when they are prescribed for patients, is critical to getting efficient care to patients.  To read the FDA announcement and summary of its final guidance on interchangeable biologics, and to access the complete final guidance, use the link below.